Mode
Text Size
Log in / Sign up

Whole-genome sequencing of fathers with children with developmental disorders shows sperm mutation burden indistinguishable from controls.

Whole-genome sequencing of fathers with children with developmental disorders shows sperm mutation b…
Photo by Rashed Moslem / Unsplash
Key Takeaway
Note that sperm mutation burden in fathers of children with developmental disorders is comparable to population reference cohorts.

This cohort study evaluated the transmissible de novo disease risk in fathers of children with developmental disorders compared to population reference cohorts. The analysis included 168 parent-child trios, with sperm sequencing performed on 127 fathers. Researchers utilized whole-genome sequencing of parent-child trios and ultra-accurate duplex sequencing of paternal sperm to assess mutation profiles.

The primary finding indicated that sperm mutation burden and mutational spectra were indistinguishable from those observed in the population reference cohorts. While the global dN/dS metric was 1.56 (95% CI 1.45-1.67) in fathers versus 1.44 (95% CI 1.17-1.77) in controls, the overall mutational load remained comparable. Additionally, 28 of 32 significantly selected genes overlapped with prior findings, reinforcing consistency with existing data.

Regarding specific variant types, early mosaic variants were harbored in 6 of 127 fathers. The allele fractions for these variants ranged from 0.7% to 14.8%. Notably, these early mosaic variants accounted for only approximately 11% of the aggregated exome pathogenic burden. No adverse events, discontinuations, or tolerability issues were reported, as this was a genetic sequencing study without pharmacological intervention.

Key limitations include the observational nature of the cohort design and the specific selection of fathers with children already diagnosed with developmental disorders. The study did not report follow-up data or specific funding conflicts. Clinicians should interpret these results as observational associations rather than causal links, acknowledging that the presence of early mosaic variants does not significantly elevate transmissible risk in this context.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
De novo mutations (DNMs) arising in the parental germline are a major cause of severe developmental disorders. While most DNMs originate in the paternal germline, it remains unclear whether fathers of affected children carry a systematically altered burden of transmissible germline risk, or whether disease largely reflects stochastic outcomes of shared population-wide mutational processes. Here, we combined whole-genome sequencing of 168 parent-child trios with ultra-accurate duplex sequencing of paternal sperm to directly relate transmitted DNMs to the broader mutational and selective landscape of the male germline. In 127 fathers, sperm mutation burden and mutational spectra were indistinguishable from population reference cohorts. Positive selection metrics were likewise concordant, with a global dN/dS of 1.56 (95% CI 1.45-1.67) compared to 1.44 (95% CI 1.17-1.77) in controls and 28 of 32 significantly selected genes overlapping with prior findings. Six fathers harboured a pathogenic early mosaic variant detectable in sperm at allele fractions that ranged from 0.7% to 14.8%. Although these variants generated substantial individual-level risk outliers, they accounted for only [~]11% of the aggregated exome pathogenic burden across the cohort. The remaining burden was distributed across low-VAF mutations, including positively selected driver variants and other rare mutations accumulating with paternal age. Together, these results show that transmissible de novo disease risk is governed primarily by universal germline mutational and selective processes, while early developmental mosaicism produces uncommon but clinically meaningful deviations. This integrated view clarifies how mutation timing, age-associated accumulation and germline selection jointly shape inheritance risk.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.